05:45
Tờ Hướng Dẫn Sử Dụng Thuốc
00:16
POWER OF ATTORNEY - POA
00:16
VARIATION: MAJOR VARIATION | MINOR VARIATION - P.8. STABILITY STUDIES
00:16
Setting dossiers for 2 APIs from 2 Manufactures
00:21
CELL - Cancer & Tumor
00:06
Manufacturer of API, DMF, GMP
00:06
Pharmaceutical process for 2 Active Pharmaceutical Ingredients from 2 manufactures
01:46
Detection: GRP78 - Bortezomib; CHOP, ATF-4, Bax and GAPDH -Trans-N-p-coumaroyl tyramine
01:56
Target to tumor-specific antigen in immunotherapy approach || Neoantigen
00:06
S.5 / P.6 Reference Standards or Materials || Hồ sơ chất chuẩn
00:11
MANUFACTURING PROCESS of vaccine [API and FP]
00:06
P.2. Pharmaceutical Development - Discriminatory properties
00:16
Bioequivalence study [BE] - Biological product
00:41
Manufacturing process and in process control - Drugs
00:11
Bioequivalence study [be] - Essential Similarity – Generic product
00:06
Drug Master File (DMF)
00:11
THE FORM OF PACKAGE INSERT FOR CAR T CELL THERAPY PRODUCT
00:11
Design: CAR-T CELL
00:11
CAR-T CELL PROCESS & CONTROL OF THE PROCESS
00:36
VALIDATION OF THE PROCEDURE – System suitability
00:06
Biological product manufacturing
00:06
Legalize / notary cho các giấy tờ pháp lý trong đăng ký thuốc
00:11
Đăng ký thuốc ở thị trường MYANMAR
00:11
CEP
00:06
P2: cỡ lô pilot, cỡ lô scaled-up và cỡ lô thương mại
00:06
Phân biệt: Thuốc biological product ≠ Thuốc Biosimilar product
00:06
Phân biệt: Thuốc Mới ≠ Thuốc Biệt dược ≠ Thuốc Generic
02:41:54
Circular 32/2018/TT-BYT - Training at the Southern of Vietnam - Part 2
X
About
Thông tin lĩnh vực đăng ký thuốc - dược phẩm
Tags